Journal
PHARMACEUTICAL PATENT ANALYST
Volume 2, Issue 2, Pages 265-289Publisher
FUTURE SCI LTD
DOI: 10.4155/PPA.12.90
Keywords
-
Categories
Funding
- NIH [CA138702]
Ask authors/readers for more resources
The PGE2 pathway is important in inflammation-driven diseases and specific targeting of the inducible mPGES-1 is warranted due to the cardiovascular problems associated with the long-term use of COX-2 inhibitors. This review focuses on patents issued on methods of measuring mPGES-1 activity, on drugs targeting mPGES-1 and on other modulators of free extracellular PGE2 concentration. Perspectives and conclusions regarding the status of these drugs are also presented. Importantly, no selective inhibitors targeting mPGES-1 have been identified and, despite the high number of published patents, none of these drugs have yet made it to clinical trials.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available